Mupirocin (lithium)

Mupirocin (lithium)

• CAS Number: 73346-79-9
• UNSPSC Description: Mupirocin (BRL-4910A) lithium is an orally active antibiotic isolated from Pseudomonas fluorescens. Mupirocin lithium apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis[1][2][3][4][5].
• Target Antigen: Antibiotic; Bacterial
• Type: Reference compound
• Related Pathways: Anti-infection
• Applications: COVID-19-immunoregulation
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/mupirocin-lithium.html
• Purity: 97.0
• Solubility: DMSO : 50 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
• Smiles: O[C@@H]1[C@@](CO[C@@H](C/C(C)=C/C(OCCCCCCCCC(O[Li])=O)=O)[C@@H]1O)([H])C[C@H]2[C@@]([C@@H](C)[C@@H](O)C)([H])O2
• Molecular Weight: 506.56
• References & Citations: [1]Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27(4):495-8.|[2]Parenti MA, et al. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm. 1987 Oct;6(10):761-70.|[3]Vingsbo Lundberg C, et al. Efficacy of topical and systemic antibiotic treatment of meticillin-resistant Staphylococcus aureus in a murine superficial skin wound infection model. Int J Antimicrob Agents. 2013 Sep. 42(3):272-5.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Phase 4